AR108844A1 - Proteínas de fusión y su aplicación en la preparación de vacunas - Google Patents

Proteínas de fusión y su aplicación en la preparación de vacunas

Info

Publication number
AR108844A1
AR108844A1 ARP170101706A ARP170101706A AR108844A1 AR 108844 A1 AR108844 A1 AR 108844A1 AR P170101706 A ARP170101706 A AR P170101706A AR P170101706 A ARP170101706 A AR P170101706A AR 108844 A1 AR108844 A1 AR 108844A1
Authority
AR
Argentina
Prior art keywords
protein
fusion
terminal end
virus
hepatitis
Prior art date
Application number
ARP170101706A
Other languages
English (en)
Original Assignee
Univ Francois Rabelais De Tours
Centre Hospitalier Regional Univ De Tours
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Francois Rabelais De Tours, Centre Hospitalier Regional Univ De Tours filed Critical Univ Francois Rabelais De Tours
Publication of AR108844A1 publication Critical patent/AR108844A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente se refiere a una proteína de fusión inmunogénica que comprende al menos los dos péptidos siguientes: a) en el extremo C-terminal, un primer péptido constituido: por la secuencia de aminoácidos de la proteína S o de la proteína M de una cepa aislada del virus humano de la hepatitis B (HBV), esta proteína S o proteína M es delecionada o no en su extremo N-terminal, y b) en el extremo N-terminal, un segundo péptido constituido: por la secuencia de aminoácidos de al menos un dominio transmembrana y del ectodominio de al menos una proteína de una cepa aislada del virus del Zika elegida entre la proteína de envoltura E o un péptido de fusión que comprende la proteína de envoltura E y la proteína prM. Reivindicación 9: Molécula de ácidos nucleicos que codifica una proteína de fusión según una cualquiera de las reivindicaciones 1 a 8. Reivindicación 11: Partícula subviral, no infecciosa e inmunogénica que comprende las proteínas siguientes: la proteína constituida por el dominio S nativo del antígeno de superficie de una cepa aislada del virus de la hepatitis B y al menos una proteína de fusión según una cualquiera de las reivindicaciones 1 a 8. Reivindicación 13: Proteína de fusión según una cualquiera de las reivindicaciones 1 a 8, para su utilización en la prevención y/o el tratamiento de la hepatitis B y/o de las infecciones ligadas al virus del Zika. Reivindicación 14: Una línea celular que expresa partículas subvirales, no infecciosas e inmunogénicas según la reivindicación 11.
ARP170101706A 2016-06-17 2017-06-21 Proteínas de fusión y su aplicación en la preparación de vacunas AR108844A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1655677A FR3052779B1 (fr) 2016-06-17 2016-06-17 Nouvelles proteines de fusion et leur application pour la preparation de vaccins

Publications (1)

Publication Number Publication Date
AR108844A1 true AR108844A1 (es) 2018-10-03

Family

ID=57233563

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101706A AR108844A1 (es) 2016-06-17 2017-06-21 Proteínas de fusión y su aplicación en la preparación de vacunas

Country Status (6)

Country Link
US (1) US10766930B2 (es)
EP (1) EP3472182A1 (es)
CN (1) CN109715649A (es)
AR (1) AR108844A1 (es)
FR (1) FR3052779B1 (es)
WO (1) WO2017216505A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021232165A1 (en) * 2020-05-22 2021-11-25 University Of Saskatchewan Recoded oncolytic viruses for treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2932388B1 (fr) * 2008-06-17 2013-03-29 Univ Rabelais Francois Nouvelles proteines de fusion et leur application pour la preparation de vaccins contre l'hepatite c
CN105821078A (zh) * 2010-12-09 2016-08-03 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法

Also Published As

Publication number Publication date
FR3052779A1 (fr) 2017-12-22
FR3052779B1 (fr) 2018-06-22
US10766930B2 (en) 2020-09-08
US20190389912A1 (en) 2019-12-26
CN109715649A (zh) 2019-05-03
EP3472182A1 (fr) 2019-04-24
WO2017216505A1 (fr) 2017-12-21

Similar Documents

Publication Publication Date Title
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
HRP20210608T1 (hr) Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
AR092796A1 (es) Composicion particulada de tipo viral
BR112017014219A2 (pt) vacinas à base de nanopartículas multivalentes
CL2013003248A1 (es) Composición inmunogenica que comprende una glucoproteina g de los virus hendra y nipah y un complejo inmunoestimulante; método para producir una respuesta de anticuerpo neutralizante contra un virus hendra y/o nipah en un sujeto.
PE20142330A1 (es) Vacuna de peptido ch3 de ige
PE20120817A1 (es) Peptidos tau antigenicos y usos de los mismos
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
PE20120563A1 (es) Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
AR108781A1 (es) Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv)
EA201892735A1 (ru) Состав вакцины против hiv
WO2018224573A8 (en) Recombinant measles virus expressing zika virus proteins and their applications
PE20240133A1 (es) Vacuna de nanoparticula a base de proteinas contra metapneumovirus
CL2019003404A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407)
IN2012DN02692A (es)
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
WO2019006401A3 (en) LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
UY37198A (es) Vacuna universal para enfermedades virales
RU2015130287A (ru) Адаптация вируса гриппа н5 к человеку
JP2016520534A5 (es)
WO2018115509A3 (en) New flavivirus vaccine
AR108844A1 (es) Proteínas de fusión y su aplicación en la preparación de vacunas
AR072156A1 (es) Proteinas de fusion y su aplicacion para la preparacion de vacunas contra la hepatitis c y b

Legal Events

Date Code Title Description
FB Suspension of granting procedure